554. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
作者: David T Rubin.;Jessica R Allegretti.;Julián Panés.;Nicole Shipitofsky.;Shadi S Yarandi.;Kuan-Hsiang Gary Huang.;Matthew Germinaro.;Rebbecca Wilson.;Hongyan Zhang.;Jewel Johanns.;Brian G Feagan.;Tadakazu Hisamatsu.;Gary R Lichtenstein.;Brian Bressler.;Laurent Peyrin-Biroulet.;Bruce E Sands.;Axel Dignass.; .
来源: Lancet. 2025年405卷10472期33-49页
Interleukin-23 inhibition is effective in treating ulcerative colitis. Guselkumab is a dual-acting, human IgG1, interleukin-23p19 subunit inhibitor that potently neutralises interleukin-23 and can bind to CD64. We aimed to evaluate the efficacy and safety of guselkumab as induction and maintenance therapy in patients with ulcerative colitis.
559. Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000-20: a retrospective analysis.
作者: Huseyin Naci.;Peter Murphy.;Beth Woods.;James Lomas.;Jinru Wei.;Irene Papanicolas.
来源: Lancet. 2025年405卷10472期50-60页
Health systems experience difficult trade-offs when paying for new drugs. In England, funding recommendations by the National Institute for Health and Care Excellence (NICE) for new drugs might generate health gains, but inevitably result in forgone health as the funds cannot be used for alternative treatments and services. We aimed to evaluate the population-health impact of NICE recommendations for new drugs during 2000-20.
|